Status:

TERMINATED

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer

Lead Sponsor:

Jonsson Comprehensive Cancer Center

Collaborating Sponsors:

Progenics Pharmaceuticals, Inc.

Conditions:

Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8

Stage II Prostate Cancer AJCC v8

Eligibility:

MALE

18+ years

Phase:

PHASE3

Brief Summary

This randomized phase III trial studies the success rate of definitive radiation therapy (dRT) for prostate cancer (PCa) with or without planning based on PSMA PET. PSMA- PET-based dRT, may improve ra...

Detailed Description

PRIMARY OBJECTIVE: I. To compare the outcome of patients with unfavorable intermediate (IR) and high-risk (HR) prostate cancer (PCa) after standard dRT versus prostate-specific membrane antigen (PSMA...

Eligibility Criteria

Inclusion

  • Adult male 18 years or older
  • Histopathologically-proven PCa
  • Unfavorable IR to HR disease:
  • Prostate specific antigen (PSA) \>= 10 ng/mL
  • Or cT-stage \>= 2b
  • Or Gleason grade 3 (4+3=7) or higher
  • Or Gleason grade 2 (3+4=7) AND \>= 50% positive biopsy cores
  • Or Decipher Score \>= 0.45
  • Treating radiation oncologist intends to incorporate PSMA PET findings into the radiotherapy plan, if patient undergoes PSMA PET (intervention arm 2)
  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study

Exclusion

  • Less than 18 years old at the time of investigational product administration
  • Extra-pelvic metastasis (M1 disease) on any imaging or biopsy done before randomization
  • Prior PSMA PET
  • Prior pelvic RT
  • Contraindications to radiotherapy (including active inflammatory bowel disease)
  • Concurrent or prior surgery or systemic therapy for PCa at the time of randomization

Key Trial Info

Start Date :

August 14 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 10 2023

Estimated Enrollment :

54 Patients enrolled

Trial Details

Trial ID

NCT04457245

Start Date

August 14 2020

End Date

January 10 2023

Last Update

January 17 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, United States, 90095